Close

Allergan (AGN) Announces Receipt of Additional Health Canada Approval for FIBRISTAL

Go back to Allergan (AGN) Announces Receipt of Additional Health Canada Approval for FIBRISTAL

FIBRISTAL®, The First And Only Medication Indicated For Uterine Fibroids, Receives Approval From Health Canada For Long Term Intermittent Treatment

November 21, 2016 8:00 AM EST

FIBRISTAL® shown to significantly control heavy uterine bleeding, shrink fibroid volume and reduce pelvic pain for patients suffering from uterine fibroids1

DUBLIN and MARKHAM, Ontario, Nov. 21, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that it has received an additional approval from Health Canada for FIBRISTAL® (ulipristal acetate, 5 mg) for the intermittent treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age. Each treatment course is three months,2 given in repeated courses.

Logo -... More